Small-molecule inhibitor and application thereof in inhibiting interaction between SUMO1 and SUMO E1

By developing small molecule inhibitors targeting the interaction between SUMO1 and SUMO E1, the problem of dysregulation of SUMO modification in diseases has been solved, effective inhibitory effects have been achieved, and new drug solutions are provided for the treatment of cancer and other diseases.

CN119055629APending Publication Date: 2024-12-03HUBEI UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310638930.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

SUMO modification is often dysregulated in cancer and other diseases. The prior art is difficult to effectively inhibit the interaction between SUMO1 and SUMO E1, resulting in difficulty in treating.

Method used

A small molecule inhibitor was developed to construct prokaryotic gene plasmids of SUMO E1 and SUMO1, express and purify the corresponding proteins, and use SDS-PAGE and MALDI-TOF and other technologies to verify the inhibitor's inhibitory effect and determine its structure and mechanism of action.

Benefits of technology

Effectively inhibit the interaction between SUMO1 and SUMO E1, and realize the treatment of related diseases, it has great application prospects and the expansion potential of treatment plans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055629A_ABST
    Figure CN119055629A_ABST
Patent Text Reader

Abstract

The invention discloses a small-molecule inhibitor aiming at protein-protein interaction and application of the small-molecule inhibitor. According to the invention, a novel small-molecule inhibitor aiming at the interaction of SUMO1 and SUMO E1 is obtained through experimental screening, and subsequent verification shows that the novel small-molecule inhibitor has good inhibitory activity, provides a potential medicine for clinically treating related diseases, and has a relatively great application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to a small molecule inhibitor for protein-protein interaction and its application; on the basis of the basic two-protein interaction, it is further expanded to a three-system protein-protein interaction, and specifically relates to the application of a small molecule inhibitor of the interaction between human SUMO1 protein and SUMO E1 protein. Background Art

[0002] Protein is a major substance that is indispensable for maintaining the normal life activities of organisms, and protein-protein interaction (PPI) is one of the important physiological functions in organisms. Research data show that more than 10,000 PPIs have been experimentally confirmed. It is estimated that the human interactome covers about 650,000 protein-protein interactions (PPIs). PPIs are essential for the formation of macromolecular structures and enzyme complexes, which form the basis of almost every cellular process from signal transduction and cell transport to catalyzing metabolic reactions, activating or inhibiting the synthesis of other proteins and biomolecules. Abnormal regulation of PPIs often causes serious diseases, such as cancer. Therefore, the study of PPIs can not only promote our understanding of molecular biology and human diseases, but also provide new targets and solutions for the development of new treatments.

[0003] Post-translational modifications (PTMs) are a very important and common process in cells, and ubiquitination is an important type of modification. SUMO protein is one of the members of ubiquitin and one of the earliest proteins discovered after ubiquitin. The SUMOylation process is mainly completed by the action of three enzymes: SUMO E1, SUMO E2, and SUMO E3. Among them, SUMO E1 consists of two subunits: Aos1 and Uba2, which mainly plays an activation role. Through the action of ATP, SUMO and SUMO E1 are connected through disulfide bonds, and then transferred to SUMO E2. Finally, under the action of SUMO E3, it is transferred to the target protein to complete SUMOylation. SUMO proteins are mainly divided into four types, including: SUMO1, SUMO2, SUMO3, and SUMO4. Among them, SUMO1 mainly enhances the stability of proteins in cells and their interactions with each other; SUMO2 and SUMO3 have a high degree of homology, often expressed as SUMO2 / 3, and their functions mainly promote protein degradation; and the research on SUMO4 is still relatively shallow. In addition, studies have shown that SUMO1 has a longer SUMOylation cycle than SUMO2 / 3, so SUMO1 is involved in the SUMOylation of most proteins in the body.

[0004] According to current research, SUMOylation modification often shows disorders in cancer, and both SUMO E2 and SUMO1 tend to be upregulated in cancer; in addition, upregulation of SUMOylation is found in bacterial and viral infections, cardiovascular, and neurodegenerative diseases. By blocking the interaction between SUMO1 and SUMO E1, SUMOylation can be effectively inhibited, thereby achieving the purpose of treating related diseases. Therefore, the development of inhibitors based on the interaction between SUMO and SUMO E1 is necessary, which will become a new type of treatment. Summary of the invention

[0005] In view of the above technical problems, the purpose of the present invention is to provide a new small molecule inhibitor targeting the interaction between SUMO1 and SUMO E1, and to provide a potential drug for the clinical treatment of related diseases.

[0006] The technical solution provided by the present invention is as follows:

[0007] In a first aspect, the present invention provides a use of a small molecule inhibitor in the preparation of a drug for inhibiting the interaction between SUMO1 and SUMO E1, characterized in that the structure of the small molecule inhibitor is as follows:

[0008]

[0009] Among them, R1 is R2 is

[0010] Furthermore, the SUMO1 protein and SUMO E1 protein are both human proteins and are key proteins for protein SUMOylation in cells.

[0011] Furthermore, the molar concentration ratio of the small molecule inhibitor in the final reaction system is in the range of small molecule: protein = 0.4: 1 to 100: 1. Preferably, the molar concentration ratio of the small molecule inhibitor in the final reaction volume is in the range of small molecule inhibitor: protein = 50: 1 to 100: 1.

[0012] Furthermore, in the protein, the molar ratio of SUMO1 to SUMO E1 is 1:1 to 6:1.

[0013] In a second aspect, the present invention provides a method for using the above-mentioned small molecule to inhibit the interaction between SUMO E1 and SUMO1, the specific steps are as follows:

[0014] 1. Construction of SUMO E1 prokaryotic gene plasmid

[0015] SUMO E1 consists of two subunits: Aos1 and Uba2

[0016] The Aos1 and Uba2 gene sequences were inserted into two pET28a plasmids through the BamHI and XhoⅠ restriction sites, respectively, to construct pET28a-His-Aos1 plasmid and pET28a-Uba2-His plasmid, which were verified by DNA sequencing;

[0017] 2. Expression of SUMO E1 fusion protein

[0018] The two plasmids constructed in step 1 were transformed into Escherichia coli BL21 strain by the CaCl2 method, screened by kanamycin, and then single colonies grown on Luria-Bertani (LB) culture plates containing kanamycin were inoculated into liquid LB medium containing kanamycin for culture, and then collected by centrifugation;

[0019] 3. Purification of SUMO E1 fusion protein

[0020] The two bacterial sludges collected in step 2 were resuspended in lysis buffer and lysed by ultrasonic method. The two protein lysates were mixed and centrifuged to retain the supernatant. Finally, Ni-NTA His tag protein binding filler was used for binding and purification to obtain human SUMO E1 fusion protein;

[0021] 4. Construction of SUMO1 prokaryotic gene plasmid

[0022] The SUMO1 gene sequence was inserted into the pET28a plasmid through the BamHI and XhoⅠ restriction sites to construct the pET28a-His-SUMO1 plasmid, which was verified by DNA sequencing;

[0023] 5. Expression of SUMO1 fusion protein

[0024] The plasmid constructed in step 3 was transformed into the Escherichia coli BL21 strain by the CaCl2 method, and selected by kanamycin. Then, a single colony grown on a Luria-Bertani (LB) culture plate containing kanamycin was inoculated into a liquid LB medium containing kanamycin for culture, and then collected by centrifugation;

[0025] 6. Purification of SUMO1 fusion protein

[0026] The bacterial sludge collected in step 5 was resuspended with lysis buffer, lysed by ultrasonic method, the protein lysate was centrifuged, and the supernatant was retained; finally, Ni-NTA His tag protein binding filler was used for binding and purification to obtain human SUMO1 fusion protein;

[0027] 7. SUMOylation Activity Test

[0028] Prepare different reaction systems, and fill each system to 100 μl with reaction solution;

[0029] Blank control group: 1 μl of 46 μM SUMO E1 protein, 1 μl of 210 μM SUMO1 protein;

[0030] Negative control group: 1 μl of 46 μM SUMO E1 protein, 1 μl of 210 μM SUMO1 protein, and 1 μl of 100 mM ATP;

[0031] Positive control group: 1 μl of 46 μM SUMO E1 protein, 1 μl of 210 μM SUMO1 protein, 1 μl of 100 mM ATP, and 1 μl of 1 M DTT;

[0032] Incubate at 37°C for 1 h and perform SDS-PAGE verification;

[0033] 8. Effect of DMSO content on the reaction

[0034] Prepare the same system as in step 7, and prepare 5 more systems as negative controls, containing 1%, 2%, 3%, 4%, and 5% DMSO respectively;

[0035] Incubate at 37°C for 1 h and perform SDS-PAGE verification;

[0036] 9. Screening of inhibitory activity

[0037] Same as step 7, prepare negative control group and positive control group, and both contain 1% DMSO;

[0038] Another experimental group was set up: 1 μl of 46 μM SUMO E1 protein, 1 μl of 210 μM SUMO1 protein, 1 μl of 100 mM ATP, and 1 μl of small molecule solutions of different concentrations;

[0039] SUMO E1 and small molecules were first incubated at 37°C for 0.5 h, followed by the addition of SUMO1 and ATP, and incubated at 37°C for 1 h; SDS-PAGE verification was performed;

[0040] 10. Verification of covalent inhibition

[0041] The same system as that configured in step 9 was used. The incubation time of SUMO E1 and small molecules was set to 0h / 0.5h / 1h / 1.5h, respectively, in a time gradient. Then SUMO1 and ATP were added and incubated at 37°C for 1h. SDS-PAGE verification was performed.

[0042] 11. MALDI-TOF covalent verification

[0043] Blank group: 10 μl of SUMO E1 was mixed with 0.2 μl of DMSO;

[0044] Experimental group: 10 μl of SUMO E1 was mixed with 0.2 μl of small molecule stock solution;

[0045] Incubate at 37°C for 1 h;

[0046] The reaction system was diluted with 0.1% TFA to a final concentration of SUMO E1 of 0.4 to 1.0 mg / ml;

[0047] Take 5 μl of the diluted reaction system and mix it with 5 μl of SA matrix;

[0048] 1 μl of the mixed sample was spotted on a metal target plate and subjected to mass spectrometry;

[0049] Use flex Control software to collect data and flex Analysis software to process data.

[0050] Further, the lysis buffer in step 3 and step 6 is: 50 mM sodium dihydrogen phosphate (NaH2PO4), pH = 8.0, 300 mM NaCl, 5 mM imidazole;

[0051] Furthermore, the reaction solution in step 7 is: 20 mM 4-hydroxyethylpiperazineethanesulfonic acid (HEPES), pH 7.5, 50 mM NaCl, 5 mM MgCl2.

[0052] Furthermore, in step 11, 0.1% (v / v) TFA is: 5 μl TFA is added to 5 ml upH2O; TA30 is: 300 μl acetonitrile is mixed with 700 μl 0.1% TFA; SA matrix is: a saturated solution of SA (sinapic acid) in TA30.

[0053] According to the above scheme, small molecules with potential inhibitory activity were experimentally screened.

[0054] The beneficial effects of the present invention are as follows:

[0055] The small molecule inhibitor provided by the present invention exhibits a good inhibitory effect on the interaction between SUMO1 and SUMO E1, effectively inhibits SUMOylation, thereby achieving the treatment of related diseases, and has great application prospects. In addition, it is also conducive to the expansion of treatment plans and the diversification of treatment approaches. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1This is a flow chart for verifying the inhibition of the interaction between SUMO1 and SUMO E1 by small molecules in the examples;

[0057] Figure 2 To verify the interaction activity between SUMO1 and SUMO E1 in Example 1;

[0058] Figure 3 The effect of DMSO on the SUMOylation reaction in Example 1;

[0059] Figure 4 A is the inhibitory effect of different concentrations of small molecules on the interaction between SUMO1 and SUMO E1 in Example 1; Figure 4 B is the inhibitory effect of the small molecule inhibitor in Example 1 after incubation with the protein for different time periods; Figure 4 C is the grayscale analysis of the Uba2-SUMO1 band at different incubation times in Example 1; Figure 4 D is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 1;

[0060] Figure 5 A is the inhibitory effect of different concentrations of small molecules on the interaction between SUMO1 and SUMO E1 in Example 2; Figure 5 B is the inhibitory effect of the small molecule inhibitor in Example 2 after incubation with the protein for different time periods; Figure 5 C is the grayscale analysis of the Uba2-SUMO1 band at different incubation times in Example 2; Figure 5 D is the mass spectrum of the molecular weight of the protein after adding small molecules in Example 2. DETAILED DESCRIPTION

[0061] The present invention is further described below in conjunction with specific embodiments, but the content of the present invention is not limited thereto at all.

[0062] Example 1

[0063] The small molecule inhibitor involved is: Compound 1, the structural formula is as follows:

[0064]

[0065] The activity detection method is as follows:

[0066] 1. Construction of SUMO E1 prokaryotic gene plasmid

[0067] SUMO E1 consists of two subunits: Aos1 and Uba2

[0068] The Aos1 and Uba2 gene sequences were inserted into two pET28a plasmids through the BamHI and XhoⅠ restriction sites, respectively, to construct pET28a-His-Aos1 plasmid and pET28a-Uba2-His plasmid, which were verified by DNA sequencing;

[0069] Human Aos1 gene sequence:

[0070]

[0071] Human Uba2 gene sequence:

[0072]

[0073] 2. Expression of SUMO E1 fusion protein

[0074] The two plasmids constructed in step 1 were transformed into Escherichia coli BL21 strain by the CaCl2 method, screened by kanamycin, and then single colonies grown on Luria-Bertani (LB) culture plates containing kanamycin were inoculated into liquid LB medium containing kanamycin, cultured at 37°C and 200 rpm until the logarithmic growth phase, and isopropylthiogalactoside (IPTG) was added to a final concentration of 1 mM, induced at 25°C for 6 hours, and then collected by centrifugation; wherein, in order to ensure that the molar amounts of the two protein subunits were the same in subsequent experiments, the bacterial liquid volume ratio of the two was set to: Aos1:Uba2=1:16;

[0075] 3. Purification of SUMO E1 fusion protein

[0076] The two bacterial sludges collected in step 2 were resuspended with lysis buffer and lysed by ultrasonic method. After mixing the two protein lysates, they were centrifuged at 4°C and 10,000 rpm, and the supernatant was retained. Finally, Ni-NTA His tag protein binding filler was used for binding and purification to obtain human SUMO E1 fusion protein. The elution buffer composition of SUMO E1 fusion protein was: 50 mM sodium dihydrogen phosphate (NaH2PO4), pH=8.0, 300 mM NaCl, 250 mM imidazole;

[0077] 4. Construction of SUMO1 prokaryotic gene plasmid

[0078] The SUMO1 gene sequence was inserted into the pET28a plasmid through the BamHI and XhoⅠ restriction sites to construct the pET28a-His-SUMO1 plasmid, which was verified by DNA sequencing;

[0079] Human SUMO1 gene sequence:

[0080] ATGTCTGACCAGGAGGCAAAACCTTCAACTGAGGACTTGGGGGATAAGAAGGAAGGTGAATATATTAAACTCAAAGTCATTGGACAGGATAGCAGTGAGATTCACTTCAAAGTGAAAATGACAACACATCTCAAGAAACTCAAAGAA TCATACTGTCAAAGACAGGGTGTTCCAATGAATTCACTCAGGTTTCCTTTGAGGGTCAGAGAATTGCTGATAATCATACTCCAAAAGAACTGGGAATGGAGGAAGAAGATGTGATTGAAGTTTATCAGGAACAAACGGGGGGTTAG

[0081] 5. Expression of SUMO1 fusion protein

[0082] The plasmid constructed in step 3 was transformed into the Escherichia coli BL21 strain by the CaCl2 method, and selected by kanamycin. Then, a single colony grown on a Luria-Bertani (LB) culture plate containing kanamycin was inoculated into a liquid LB medium containing kanamycin, and cultured at 37°C and 200 rpm until the logarithmic growth phase. Isopropylthiogalactoside (IPTG) was added to a final concentration of 1 mM, and induced at 25°C for 6 h, followed by collection by centrifugation;

[0083] 6. Purification of SUMO1 fusion protein

[0084] The bacterial sludge collected in step 5 was resuspended with lysis buffer, lysed by ultrasonic method, and the protein lysate was centrifuged at 4°C and 10,000 rpm, and the supernatant was retained; finally, Ni-NTA His tag protein binding filler was used for binding and purification to obtain human SUMO1 fusion protein, and the elution buffer composition of SUMO1 fusion protein was: 50mM sodium dihydrogen phosphate (NaH2PO4), pH=8.0, 300mM NaCl, 250mM imidazole;

[0085] 7. SUMOylation Activity Test

[0086] Configure different reaction systems, and fill each system to 100 μl with reaction solution.

[0087] Blank control group: 1 μl of 46 μM SUMO E1 protein, 1 μl of 210 μM SUMO1 protein;

[0088] Negative control group: 1 μl of 46 μM SUMO E1 protein, 1 μl of 210 μM SUMO1 protein, and 1 μl of 100 mM ATP;

[0089] Positive control group: 1 μl of 46 μM SUMO E1 protein, 1 μl of 210 μM SUMO1 protein, 1 μl of 100 mM ATP, and 1 μl of 1 M DTT;

[0090] Incubate at 37°C for 1 h and perform SDS-PAGE verification;

[0091] 8. Effect of DMSO content on the reaction

[0092] Prepare the same system as in step 7, and prepare 5 more systems as negative controls, containing 1%, 2%, 3%, 4%, and 5% (v / v) DMSO respectively;

[0093] Incubate at 37°C for 1 h and perform SDS-PAGE verification;

[0094] 9. Screening of inhibitory activity

[0095] As in step 7, a negative control group and a positive control group were prepared, and both contained 1% (v / v) DMSO;

[0096] Another experimental group was set up: 1 μl of 46 μM SUMO E1 protein, 1 μl of 210 μM SUMO1 protein, 1 μl of 100 mM ATP, and 1 μl of small molecule solutions of different concentrations;

[0097] SUMO E1 and small molecules were first incubated at 37°C for 0.5 h, followed by the addition of SUMO1 and ATP, and incubated at 37°C for 1 h; SDS-PAGE verification was performed;

[0098] The inhibitory effect of the small molecule inhibitor obtained by the above method is as follows Figure 4 As shown in A, the concentration of small molecules in the gel image gradually increased from 0μM to 100μM. It can be seen that with the continuous increase in the concentration of small molecules, the band of Uba2-SUMO1 gradually faded, which reflects that the inhibitory effect gradually increased with the concentration of small molecules, reflecting that small molecules have good concentration dependence;

[0099] 10. Verification of covalent inhibition

[0100] The same system as that configured in step 9 was used. The incubation time of SUMO E1 and small molecules was set to 0h / 0.5h / 1h / 1.5h, respectively, in a time gradient. Then SUMO1 and ATP were added and incubated at 37°C for 1h. SDS-PAGE verification was performed.

[0101] According to the above method, the inhibitory effects of the small molecule inhibitor at different incubation times are obtained as follows: Figure 4 B, then the grayscale analysis of the Uba2-SUMO1 bands at different incubation times was performed. Figure 4 C, From the figure, it can be seen that with the extension of incubation time, the concentration of small molecules required to inhibit SUMOylation tends to decrease;

[0102] 11. MALDI-TOF covalent verification

[0103] Blank group: 10 μl of SUMO E1 was mixed with 0.2 μl of DMSO;

[0104] Experimental group: 10 μl of SUMO E1 was mixed with 0.2 μl of small molecule stock solution;

[0105] Incubate at 37°C for 1 h;

[0106] The reaction system was diluted with 0.1% TFA to a final concentration of SUMO E1 of 0.4 to 1.0 mg / ml;

[0107] Take 5 μl of the diluted reaction system and mix it with 5 μl of SA matrix;

[0108] Take 1 μl of the mixed sample and spot it on the metal target plate for mass spectrometry detection;

[0109] Use flex Control software to collect data and flex Analysis software to process data.

[0110] Figure 4 As can be seen from the mass spectrum of D, the molecular weight of the experimental group (black) with the addition of small molecules has shifted significantly to the right compared with the blank group (gray), which indicates that the small molecules are covalently bound to the protein.

[0111] Example 2

[0112] The small molecule inhibitor involved is: Compound 2, with the structural formula:

[0113]

[0114] The activity detection method is the same as in Example 1.

[0115] The test results are as follows:

[0116] Figure 5 A shows that the concentration of small molecules ranges from 100 μM to 0 μM from the left to the right in the gel image. It can be seen that as the concentration of small molecules increases, the inhibitory effect gradually increases.

[0117] Figure 5 B and 5C, it can be seen that as the incubation time increases, the concentration of small molecules required to inhibit SUMOylation tends to decrease.

[0118] Figure 5 As can be seen from the mass spectrum of D, the molecular weight of the experimental group (black) with the addition of small molecules has shifted significantly to the right compared with the blank group (gray), which indicates that the small molecules are covalently bound to the protein.

[0119] The above description is only a preferred specific implementation manner of the present invention, but the scope of protection of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention should be included in the scope of protection of the invention.

Claims

1. Use of a small molecule inhibitor in the preparation of a drug for inhibiting the interaction between SUMO1 and SUMO E1, characterized in that: The structure of the small molecule inhibitor is as follows: Among them, R1 is R2 is 2. Use of the small molecule inhibitor according to claim 1 in the preparation of a drug for inhibiting the interaction between SUMO1 and SUMO E1, characterized in that: The SUMO1 protein and SUMO E1 protein are both human proteins.

3. Use of the small molecule inhibitor according to claim 1 in the preparation of a drug for inhibiting the interaction between SUMO1 and SUMO E1, characterized in that: The molar concentration ratio of the small molecule inhibitor in the final reaction system ranges from small molecule to protein = 0.4:1 to 100:1.